DelveInsight's "Beta-thalassemia Market Insights, Epidemiology and Market Forecast-2028" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of B-thal in the Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan and China.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Beta-thalassemia (B-thal) from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
• Turkey, Russia, China and Taiwan
• Latin-America(Colombia, Brazil, Argentina, Mexico)
• Middle-east (Saudi Arabia, UAE)
Beta-thalassemia is an inherited disorder that is a result of various mutations (over 200 disease-causing mutations have been identified) or, rarely, deletions of the beta-globin gene (HbB) on chromosome 11. About three percent of adult hemoglobin is made of alpha and delta chains. Just as with beta-thalassemia, mutations that affect the ability of the delta gene to produce delta chains can occur leading to delta thalassemia. Beta-thalassemia includes three main forms; Thalassemia Major variably referred to as "Cooley's Anemia" and "Mediterranean Anemia", Thalassemia Intermediate and Thalassemia Minor also called "beta-thalassemia carrier", "beta-thalassemia trait," or "heterozygous beta-thalassemia".
The DelveInsight Beta-thalassemia (B-thal) market report gives the thorough understanding of the Beta-thalassemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Beta-thalassemia in the 10 emerging markets.
The Beta-thalassemia (B-thal) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging market countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases of B-thal, total diagnosed prevalence, diagnosed prevalence by disease type and complications associated with B-thal) scenario of Beta-thalassemia (B-thal) in the 10EM covering Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan and China from 2017-2028.
According to DelveInsight, the total number of prevalent cases of Beta-thalassemia (B-thal) in 10EM was found to be 64,655, in the year 2017.
This segment of the Beta-thalassemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Blood-transfusion Therapies form the mainstay of treatment landscape of Beta-thalassemia despite major limitations. The primary hindrance lies in the fact that there is major chances of iron overload, heart failure, arrhythmias, cirrhosis, hepatocellular carcinoma, osteoporosis, stunted growth, thrombophilia, diabetes, hyper and hypo thyroidism and gonadism etc. Despite these limitations, iron chelators are the treatment of choice and generate the maximum amount of revenue.
The Beta-thalassemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Beta-thalassemia in 10EM was found to be USD 201.10 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 10EM, China accounts for the largest market size of Beta-thalassemia, in comparison to other emerging market countries.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
• 10 Year Forecast
• 10EM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Beta-thalassemia market
• Organize sales and marketing efforts by identifying the best opportunities for Beta-thalassemia market
• To understand the future market competition in the Beta-thalassemia market.
1 Key Insights
2 ?-thalassemia Market Overview at a Glance
2.1 Market Share (%) Distribution of ? -thalassemia in 2017
2.2 Market Share (%) Distribution of ? -thalassemia in 2028
3 Disease Background and Overview
3.1 Introduction
3.2 Types
3.3 Molecular Genetics
3.4 Causes and risk factors
3.5 Complications associated with Beta-thalassemia
3.6 Etiology
3.7 Symptoms
3.8 Pathophysiology
3.9 Clinical Presentation of Beta-Thalassemia
3.1 Diagnosis
4 Epidemiology and Patient Population
4.1 Key Findings
4.2 Total Diagnosed Prevalence of ?-thal in 10 Emerging Markets
5 Country Wise-Epidemiology of Beta-Thal
5.1 Assumptions and Rationale
5.2 China
5.2.1 Total Prevalent Cases of ?-thal in China
5.2.2 Diagnosed Prevalence of ?-thal in China
5.2.3 Diagnosed ?-thal Patients by Disease Type in China
5.2.4 Complications of ?-thalassemia Patients in China
5.3 Taiwan
5.3.1 Total Prevalent Cases of ?-thal in Taiwan
5.3.2 Diagnosed Prevalence of ?-thal in Taiwan
5.3.3 Diagnosed ?-thal Patients by Disease Type in Taiwan
5.3.4 Complications of ?-thalassemia Patients in Taiwan
5.4 Saudi Arabia
5.4.1 Total Prevalent Cases of ?-thal in Saudi Arabia
5.4.2 Diagnosed Prevalence of ?-thal in Saudi Arabia
5.4.3 Diagnosed ?-thal Patients by Disease Type in Saudi Arabia
5.4.4 Complications of ?-thalassemia Patients in Saudi Arabia
5.5 UAE
5.5.1 Total Prevalent Cases of ?-thal in UAE
5.5.2 Diagnosed Prevalence of ?-thal in UAE
5.5.3 Diagnosed ?-thal Patients by Disease Type in UAE
5.5.4 Complications of ?-thalassemia Patients in UAE
5.6 Turkey
5.6.1 Total Prevalent Cases of ?-thal in Turkey
5.6.2 Diagnosed Prevalence of ?-thal in Turkey
5.6.3 Diagnosed ?-thal Patients by Disease Type in Turkey
5.6.4 Complications of ?-thalassemia Patients in Turkey
5.7 Russia
5.7.1 Total Prevalent Cases of ?-thal in Russia
5.7.2 Diagnosed Prevalence of ?-thal in Russia
5.7.3 Diagnosed ?-thal Patients by Disease Type in Russia
5.7.4 Complications of ?-thalassemia Patients in Russia
5.8 Colombia
5.8.1 Total Prevalent Cases of ?-thal in Colombia
5.8.2 Diagnosed Prevalence of ?-thal in Colombia
5.8.3 Diagnosed ?-thal Patients by Disease Type in Colombia
5.8.4 Complications of ?-thalassemia Patients in Colombia
5.9 Brazil
5.9.1 Total Prevalent Cases of ?-thal in Brazil
5.9.2 Diagnosed Prevalence of ?-thal in Brazil
5.9.3 Diagnosed ?-thal Patients by Disease Type in Brazil
5.9.4 Complications of ?-thalassemia Patients in Brazil
5.1 Argentina
5.10.1 Total Prevalent Cases of ?-thal in Argentina
5.10.2 Diagnosed Prevalence of ?-thal in Argentina
5.10.3 Diagnosed ?-thal Patients by Disease Type in Argentina
5.10.4 Complications of ?-thalassemia Patients in Argentina
5.11 Mexico
5.11.1 Total Prevalent Cases of ?-thal in Mexico
5.11.2 Diagnosed Prevalence of ?-thal in Mexico
5.11.3 Diagnosed ?-thal Patients by Disease Type in Mexico
5.11.4 Complications of ?-thalassemia Patients in Mexico
6 Treatment and Management of Beta-thalassemia
6.1 Transfusion therapy
6.2 Iron Chelation Therapy
6.3 Treatment of Iron-overload Complications
6.4 Bone Marrow and Cord Blood Transplantation
6.5 Fetal Hemoglobin Induction
6.6 Gene therapy
7 Unmet Needs
8 Organizations contributing towards Beta-thalassemia
9 KOL Views: Beta-thalassemia
10 Case Studies
10.1 Quality of Life and Depression in Turkish Patients with Beta-thalassemia Major: A Cross-Sectional Study
10.2 Very mild forms of Hb S/beta+-thalassemia in Brazilian children
10.3 Prevalence of Beta-thalassemia trait in premarital screening in Al-Hassa, Saudi Arabia
10.4 Deferiprone or Deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan
10.5 Molecular prenatal diagnosis of alpha and beta thalassemia in pregnant Hakka women in southern China
11 Marketed Drugs
11.1 Desferal: Novartis
11.1.1 Product Description
11.1.2 Regulatory Milestones
11.1.3 Generic Availability
11.1.4 Advantages & Disadvantages
11.1.5 Product Profile
11.2 Exjade: Novartis
11.2.1 Product Description
11.2.2 Regulatory Milestones
11.2.3 Generic Availability
11.2.4 Advantages & Disadvantages
11.2.5 Product Profile
11.3 Ferrirpox (deferiprone): Apotex
11.3.1 Drug Description
11.3.2 Regulatory Milestones
11.3.3 Advantages & Disadvantages
11.3.4 Product Profile
12 Emerging Therapies
12.1 LentiGlobin BB305: BlueBird Bio
12.1.1 Product Description
12.1.2 Other Development Activities
12.1.3 Clinical Development
12.1.3.1 Clinical Trials Information
12.1.4 Safety and Efficacy
12.1.5 Product Profile
12.2 ACE-536: Acceleron Pharma/Celgene Corporation
12.2.1 Product Description
12.2.2 Other Developmental Activities
12.2.3 Clinical Development
12.2.3.1 Clinical Trials Information
12.2.4 Safety and Efficacy
12.2.5 Product Profile
12.3 PTG-300: Protagonist Therapeutics
12.3.1 Product Description
12.3.2 Other Developmental Activities
12.3.3 Clinical Development
12.3.3.1 Clinical Trials Information
12.3.4 Safety and Efficacy
12.3.5 Product Profile
12.4 ACE-011 (Sotatercept): Acceleron Pharma/Celgene Corporation
12.4.1 Product Description
12.4.2 Other Developmental Activities
12.4.3 Clinical Development
12.4.3.1 Clinical Trials Information
12.4.4 Safety and Efficacy
12.4.5 Product Profile
12.5 LJPC-401: La Jolla Pharmaceutical Company
12.5.1 Product Description
12.5.2 Other Developmental Activities
12.5.3 Clinical development
12.5.3.1 Clinical Trials Information
12.5.4 Safety and Efficacy
12.5.5 Product Profile
13 Other Promising Therapies
13.1 Tipadena (Thiotepa): Adienne SA
13.1.1 Product description
13.1.2 Product Profile
14 Beta-thalassemia : 10 EM Market Analysis
14.1 Key Findings
14.2 Market Size of ?-thalassemia in 10 EM
14.2.1 Market Size of ?-thal by Therapies
15 Market Outlook by Country
15.1 Emerging Markets: Market Outlook
15.2 China
15.2.1 Total Market Size of Beta-thalassemia
15.2.2 Market Size of Beta-thalassemia by Therapies
15.3 Taiwan
15.3.1 Total Market Size of Beta-thalassemia
15.3.2 Market Size of Beta-thalassemia by Therapies
15.4 Saudi Arabia
15.4.1 Total Market Size of Beta-thalassemia
15.4.2 Market Size of Beta-thalassemia by Therapies
15.5 UAE
15.5.1 Total Market Size of Beta-thalassemia
15.5.2 Market Size of Beta-thalassemia by Therapies
15.6 Turkey
15.6.1 Total Market Size of Beta-thalassemia
15.6.2 Market Size of Beta-thalassemia by Therapies
15.7 Russia
15.7.1 Total Market Size of Beta-thalassemia
15.7.2 Market Size of Beta-thalassemia by Therapies
15.8 Colombia
15.8.1 Total Market Size of Beta-thalassemia
15.8.2 Market Size of Beta-thalassemia by Therapies
15.9 Brazil
15.9.1 Total Market Size of Beta-thalassemia
15.9.2 Market Size of Beta-thalassemia by Therapies
15.1 Argentina
15.10.1 Total Market Size of Beta-thalassemia
15.10.2 Market Size of Beta-thalassemia by Therapies
15.11 Mexico
15.11.1 Total Market Size of Beta-thalassemia
15.11.2 Market Size of Beta-thalassemia by Therapies
16 Market Barriers
17 Market Drivers
18 Appendix
18.1 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
Table 1: Difference between Beta-thalassemia major and intermediate based on different parameters
Table 2: Diagnosed Prevalence of ?-thal in 10 Emerging Markets (2017-2028)
Table 3: Total Prevalent Cases ?-thal in China (2017-2028)
Table 4: Diagnosed Prevalence of ?-thal in China (2017-2028)
Table 5: Diagnosed ?-thal Patients by Disease Type in China (2017-2028)
Table 6: Complications of ?-thalassemia Patients in China (2017-2028)
Table 7: Total Prevalence Cases of ?-thal in Taiwan (2017-2028)
Table 8: Diagnosed Prevalence of ?-thal by Types in Taiwan (2017-2028)
Table 9: Diagnosed ?-thal Patients by Disease Type in Taiwan (2017-2028)
Table 10: Complications of ?-thalassemia Patients in Taiwan (2017-2028)
Table 11: Total Prevalence Cases of ?-thal in Saudi Arabia (2017-2028)
Table 12: Diagnosed Prevalence of ?-thal in Saudi Arabia (2017-2028)
Table 13: Diagnosed ?-thal Patients by Disease Type in Saudi Arabia (2017-2028)
Table 14: Complications of ?-thalassemia Patients in Saudi Arabia (2017-2028)
Table 15: Total Prevalence Cases of ?-thal in UAE (2017-2028)
Table 16: Diagnosed Prevalence of ?-thal in UAE (2017-2028)
Table 17: Diagnosed ?-thal Patients by Disease Type in UAE (2017-2028)
Table 18: Complications of ?-thalassemia Patients in UAE (2017-2028)
Table 19: Total Prevalence Cases of ?-thal in Turkey (2017-2028)
Table 20: Diagnosed Prevalence of ?-thal in Turkey (2017-2028)
Table 21: Diagnosed ?-thal Patients by Disease Type in Turkey (2017-2028)
Table 22: Complications of ?-thalassemia Patients in Turkey (2017-2028)
Table 23: Total Prevalence Cases of ?-thal in Russia (2017-2028)
Table 24: Diagnosed Prevalence of ?-thal in Russia (2017-2028)
Table 25: Diagnosed ?-thal Patients by Disease Type in Russia (2017-2028)
Table 26: Complications of ?-thalassemia Patients in Russia (2017-2028)
Table 27: Total Prevalence Cases of ?-thal in Colombia (2017-2028)
Table 28: Diagnosed Prevalence of ?-thal in Colombia (2017-2028)
Table 29: Diagnosed ?-thal Patients by Disease Type in Colombia (2017-2028)
Table 30: Complications of ?-thalassemia Patients in Colombia (2017-2028)
Table 31: Total Prevalence Cases of ?-thal in Brazil (2017-2028)
Table 32: Diagnosed Prevalence of ?-thal in Brazil (2017-2028)
Table 33: Diagnosed ?-thal Patients by Disease Type in Brazil (2017-2028)
Table 34: Complications of ?-thalassemia Patients in Brazil (2017-2028)
Table 35: Total Prevalence Cases of ?-thal in Argentina (2017-2028)
Table 36: Diagnosed Prevalence of ?-thal in Argentina (2017-2028)
Table 37: Diagnosed ?-thal Patients by Disease Type in Argentina (2017-2028)
Table 38: Complications of ?-thalassemia Patients in Argentina (2017-2028)
Table 39: Total Prevalence Cases of ?-thal in Mexico (2017-2028)
Table 40: Diagnosed Prevalence of ?-thal in Mexico (2017-2028)
Table 41: Diagnosed ?-thal Patients by Disease Type in Mexico (2017-2028)
Table 42: Complications of ?-thalassemia Patients in Mexico (2017-2028)
Table 43: Comparison of three leading iron chelators for treatment of beta-thalassemia
Table 44: Frequencies of various complications and treatment of Beta-thalassemia
Table 45: Organizations contributing toward Beta-thalassemia
Table 46: LentiGlobin BB305, Clinical Trial Description 2019
Table 47: ACE-536, Clinical Trial Description 2019
Table 48: PGT-300, Clinical Trial Description 2019
Table 49: ACE-011, Clinical Trial Description 2019
Table 50: LJPC-401, Clinical Trial Description 2019
Table 51: Total Market Size of ?-thal in 10 Emerging Markets in USD Million (2017-2028)
Table 52: Total Market Size of ?-thal by Therapies in 10 Emerging Markets in USD Million (2017-2028)
Table 53: Total Market Size of ?-thal in China, USD Million (2017-2028)
Table 54: China Market Size of ?-thal by Therapies in USD Million (2017-2028)
Table 55: Total Market Size of ?-thal in Taiwan, USD Million (2017-2028)
Table 56: Taiwan Market Size of ?-thal by Therapies in USD Million (2017-2028)
Table 57: Total Market Size of ?-thal in Saudi Arabia, USD Million (2017-2028)
Table 58: Saudi Arabia Market Size of ?-thal by Therapies in USD Million (2017-2028)
Table 59: Total Market Size of ?-thal in UAE, USD Million (2017-2028)
Table 60: UAE Market Size of ?-thal by Therapies in USD Million (2017-2028)
Table 61: Total Market Size of ?-thal in Turkey, USD Million (2017-2028)
Table 62: Turkey Market Size of ?-thal by Therapies in USD Million (2017-2028)
Table 63: Total Market Size of ?-thal in Russia, USD Million (2017-2028)
Table 64: Russia Market Size of ?-thal by Therapies in USD Million (2017-2028)
Table 65: Total Market Size of ?-thal in Colombia, USD Million (2017-2028)
Table 66: Colombia Market Size of ?-thal by Therapies in USD Million (2017-2028)
Table 67: Total Market Size of ?-thal in Brazil, USD Million (2017-2028)
Table 68: Brazil Market Size of ?-thal by Therapies in USD Million (2017-2028)
Table 69: Total Market Size of ?-thal in Argentina, USD Million (2017-2028)
Table 70: Argentina Market Size of ?-thal by Therapies in USD Million (2017-2028)
Table 71: Total Market Size of ?-thal in Mexico, USD Million (2017-2028)
Table 72: Mexico Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 1: Chromosome 11
Figure 2: Red blood cells
Figure 3: Classification of Beta-thalassemia by
Figure 4: Inheritance pattern of Beta-thalassemia
Figure 5: Possible complications associated with Beta-thalassemia
Figure 6: Symptoms of Beta-thalassemia
Figure 7: Pathophysiology of Beta-thalassemia
Figure 8: Clinical and Psychosocial concerns among patient's in different age-groups
Figure 9: Diagnostic algorithm of Beta-thalassemia
Figure 10: Diagnosed Prevalence of ?-thal in 10 Emerging Markets (2017-2028)
Figure 11: Total Prevalent Cases of ?-thal in China (2017-2028)
Figure 12: Diagnosed Prevalence of ?-thal in China (2017-2028)
Figure 13: Diagnosed ?-thal Patients by Disease Type in China (2017-2028)
Figure 14: Complications of ?-thalassemia Patients in China (2017-2028)
Figure 15: Total Prevalence Cases of ?-thal in Taiwan (2017-2028)
Figure 16: Diagnosed Prevalence of ?-thal by Types in Taiwan (2017-2028)
Figure 17: Diagnosed ?-thal Patients by Disease Type in Taiwan (2017-2028)
Figure 18: Complications of ?-thalassemia Patients in Taiwan (2017-2028)
Figure 19: Total Prevalence Cases of ?-thal in Saudi Arabia (2017-2028)
Figure 20: Diagnosed Prevalence of ?-thal in Saudi Arabia (2017-2028)
Figure 21: Diagnosed ?-thal Patients by Disease Type in Saudi Arabia (2017-2028)
Figure 22: Complications of ?-thalassemia Patients in Saudi Arabia (2017-2028)
Figure 23: Total Prevalence Cases of ?-thal in UAE (2017-2028)
Figure 24: Diagnosed Prevalence of ?-thal in UAE (2017-2028)
Figure 25: Diagnosed ?-thal Patients by Disease Type in UAE (2017-2028)
Figure 26: Complications of ?-thalassemia Patients in UAE (2017-2028)
Figure 27: Total Prevalence Cases of ?-thal in Turkey (2017-2028)
Figure 28: Diagnosed Prevalence of ?-thal in Turkey (2017-2028)
Figure 29: Diagnosed ?-thal Patients by Disease Type in Turkey (2017-2028)
Figure 30: Complications of ?-thalassemia Patients in Turkey (2017-2028)
Figure 31: Total Prevalence Cases of ?-thal in Russia (2017-2028)
Figure 32: Diagnosed Prevalence of ?-thal in Russia (2017-2028)
Figure 33: Diagnosed ?-thal Patients by Disease Type in Russia (2017-2028)
Figure 34: Complications of ?-thalassemia Patients in Russia (2017-2028)
Figure 35: Total Prevalence Cases of ?-thal in Colombia (2017-2028)
Figure 36: Diagnosed Prevalence of ?-thal in Colombia (2017-2028)
Figure 37: Diagnosed ?-thal Patients by Disease Type in Colombia (2017-2028)
Figure 38: Complications of ?-thalassemia Patients in Colombia (2017-2028)
Figure 39: Total Prevalence Cases of ?-thal in Brazil (2017-2028)
Figure 40: Diagnosed Prevalence of ?-thal in Brazil (2017-2028)
Figure 41: Diagnosed ?-thal Patients by Disease Type in Brazil (2017-2028)
Figure 42: Complications of ?-thalassemia Patients in Brazil (2017-2028)
Figure 43: Total Prevalence Cases of ?-thal in Argentina (2017-2028)
Figure 44: Diagnosed Prevalence of ?-thal in Argentina (2017-2028)
Figure 45: Diagnosed ?-thal Patients by Disease Type in Argentina (2017-2028)
Figure 46: Complications of ?-thalassemia Patients in Argentina (2017-2028)
Figure 47: Total Prevalence Cases of ?-thal in Mexico (2017-2028)
Figure 48: Diagnosed Prevalence of ?-thal in Mexico (2017-2028)
Figure 49: Diagnosed ?-thal Patients by Disease Type in Mexico (2017-2028)
Figure 50: Complications of ?-thalassemia Patients in Mexico (2017-2028)
Figure 51: Overview of current management of Beta-Thalassemia
Figure 52: Beta-thalassemia and its severity based on transfusion dependency
Figure 53: Amelioration of ROS by iron chelators and antioxidants
Figure 54: Unmet needs
Figure 55: Total Market Size of ?-thal in 10 Emerging Markets in USD Million (2017-2028)
Figure 56: Total Market Size of ?-thal by Therapies in 10 Emerging Markets in USD Million (2017-2028)
Figure 57: Total Market Size of ?-thal in China, USD Million (2017-2028)
Figure 58: China Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 59: Total Market Size of ?-thal in Taiwan, USD Million (2017-2028)
Figure 60: Taiwan Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 61: Total Market Size of ?-thal in Saudi Arabia, USD Million (2017-2028)
Figure 62: Saudi Arabia Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 63: Total Market Size of ?-thal in UAE, USD Million (2017-2028)
Figure 64: UAE Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 65: Total Market Size of ?-thal in Turkey, USD Million (2017-2028)
Figure 66: Turkey Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 67: Total Market Size of ?-thal in Russia, USD Million (2017-2028)
Figure 68: Russia Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 69: Total Market Size of ?-thal in Colombia, USD Million (2017-2028)
Figure 70: Colombia Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 71: Total Market Size of ?-thal in Brazil, USD Million (2017-2028)
Figure 72: Brazil Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 73: Total Market Size of ?-thal in Argentina, USD Million (2017-2028)
Figure 74: Argentina Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 75: Total Market Size of ?-thal in Mexico, USD Million (2017-2028)
Figure 76: Mexico Market Size of ?-thal by Therapies in USD Million (2017-2028)
Figure 77: Market Barriers
Figure 78: Market Drivers
